Oncology · RYBREVANT. Non Small Cell Lung Cancer 2L (MARIPOSA-2) · RYBREVANT / LAZCLUZE. Non Small Cell Lung Cancer (MARIPOSA) · IMBRUVICA (ibrutinib). Frontline ...

Major US/EU approvals and submissions and phase 2/3 clinical data presentations being planned or achieved for the year. Learn more. U.S. patent expiry tables. Development pipeline · Novel therapies · 2024 Key events

Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Johnson & Johnson.

Этот раздел глобального веб-сайта Janssen содержит информацию о компании на нескольких языках. Он не предназначен для какой-либо определенной аудитории или ...

Explore Johnson & Johnson with its drug pipeline, therapeutic area, technology platform, 5 clinical trials, 5 news, and 24 literature, ...

16 окт. 2024 г. · Johnson & Johnson has discontinued the development of a handful of early- and mid-stage drug candidates, most of which were being advanced for ...

15 окт. 2024 г. · Johnson & Johnson cut a handful of trials across its portfolio in the third quarter, including a Phase 2 study of a touted neuroscience treatment.

This section of the global Janssen website provides a company overview in several languages. It is not targeted to any specific audience or country.

11 июл. 2024 г. · The Company is leveraging a multi-pathway approach to transform treatment in atopic dermatitis and other immune-mediated diseases.

PIPE-307 is an oral, highly selective antagonist of the muscarinic M1 receptor, which has completed two Phase 1 clinical trials in healthy patients.